Pharmaceuticals

Melissa Krebs Shares Gersana’s Vision for Innovative Wound Care Solutions

bexib
By bexib 0 Min Read

In this interview, Melissa Krebs, CEO and Founder of GelSana, discusses the journey of developing a cutting-edge biomaterial that has the potential to transform the $78 billion wound care market.

You Might Also Like

CDC advisory committee unanimously recommends Vaxelis for prevention of invasive Haemophilus influenzae type B infections in American Indian and Alaska Native infants

Degron Therapeutics and Takeda Enter into Exclusive License and Collaboration Agreement to Develop Molecular Disintegrators for Multiple Indications

Quest Diagnostics Acquires University Hospital Outreach Laboratory Services Assets

Study finds headache medicine may prevent acute migraine medication overuse

Synthetic Lethality: Q&A with Oren Gilad, CEO of Aprea Therapeutics

Share This Article
Previous Article Calculated Risk: Update: Lumber prices unchanged year-over-year
Next Article Efficient and Inefficient – Econlib
Leave a Comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Stay Connected

Latest News

Rebble is opposite to non -profit organizations, hackathon, and the ambition of the OS.
Manufacturing
Trump 2.0 regulators’ pullbacks can cause changes
Banking
Podcast: Banks as tech providers for SMB clients
Banking
American personal protective equipment manufacturers gather in California
Manufacturing